Bionews, Inc., the parent company of this site, has partnered with the following nonprofit advocacy organizations to help further the mission of ensuring that patients and caregivers are able to get ...
Treatment with antimiRs, an RNA-based therapy approach, was able to correct molecular defects in a cell model of myotonic dystrophy type 1 (DM1) — a form of muscular dystrophy — according to the ...